These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26338686)

  • 41. Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study.
    Cid Ruzafa J; Paczkowski R; Boye KS; Di Tanna GL; Sheetz MJ; Donaldson R; Breyer MD; Neasham D; Voelker JR
    Int J Clin Pract; 2015 Aug; 69(8):871-82. PubMed ID: 26011029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study.
    Pugliese G; Solini A; Bonora E; Fondelli C; Orsi E; Nicolucci A; Penno G;
    Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):815-22. PubMed ID: 24780515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study.
    Sukkar L; Kang A; Hockham C; Young T; Jun M; Foote C; Pecoits-Filho R; Neuen B; Rogers K; Pollock C; Cass A; Sullivan D; Wong G; Knight J; Peiris D; Gallagher M; Jardine M;
    Diabetes Care; 2020 May; 43(5):982-990. PubMed ID: 32161053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes.
    Viazzi F; Piscitelli P; Giorda C; Ceriello A; Genovese S; Russo GT; Fioretto P; Guida P; De Cosmo S; Pontremoli R;
    J Diabetes Complications; 2017 Feb; 31(2):419-426. PubMed ID: 27884661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort study.
    Hung AM; Hackstadt AJ; Griffin MR; Grijalva CG; Greevy RA; Roumie CL
    CMAJ Open; 2023; 11(1):E77-E89. PubMed ID: 36720491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
    del Pozo-Fernández C; Pardo-Ruiz C; Sánchez-Botella C; Blanes-Castañer V; López-Menchero R; Gisbert-Sellés C; Sánchez-Jodar C; Alvarez-Avellán L
    Nefrologia; 2012 May; 32(3):367-73. PubMed ID: 22592422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.
    Jiang G; Luk AOY; Tam CHT; Xie F; Carstensen B; Lau ESH; Lim CKP; Lee HM; Ng ACW; Ng MCY; Ozaki R; Kong APS; Chow CC; Yang X; Lan HY; Tsui SKW; Fan X; Szeto CC; So WY; Chan JCN; Ma RCW;
    Kidney Int; 2019 Jan; 95(1):178-187. PubMed ID: 30415941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Could metformin be used in patients with diabetes and advanced chronic kidney disease?
    Chowdhury TA; Srirathan D; Abraham G; Oei EL; Fan SL; McCafferty K; Yaqoob MM
    Diabetes Obes Metab; 2017 Feb; 19(2):156-161. PubMed ID: 27690331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prevalence of normoalbuminuria and renal impairment in type 2 diabetes mellitus
.
    Pichaiwong W; Homsuwan W; Leelahavanichkul A
    Clin Nephrol; 2019 Aug; 92(2):73-80. PubMed ID: 31198168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control.
    Hung AM; Roumie CL; Greevy RA; Liu X; Grijalva CG; Murff HJ; Griffin MR
    Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):623-31. PubMed ID: 23592561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.
    Kwon S; Kim YC; Park JY; Lee J; An JN; Kim CT; Oh S; Park S; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
    Diabetes Care; 2020 May; 43(5):948-955. PubMed ID: 32132005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients.
    Šálek T; Adamíková A
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):298-302. PubMed ID: 30218617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analgesia dose prescribing and estimated glomerular filtration rate decline: a general practice database linkage cohort study.
    Nderitu P; Doos L; Strauss VY; Lambie M; Davies SJ; Kadam UT
    BMJ Open; 2014 Aug; 4(8):e005581. PubMed ID: 25138808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of serum creatinine and kidney function among incident metformin users.
    Schorr M; Hemmelgarn BR; Tonelli M; Soo A; Manns BJ; Bresee LC;
    Can J Diabetes; 2013 Aug; 37(4):226-230. PubMed ID: 24070885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
    Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
    Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
    Xie Y; Bowe B; Gibson AK; McGill JB; Yan Y; Maddukuri G; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2785-2795. PubMed ID: 32912850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.